Stay up to date with the latest Mycovia news, press releases, and more. If you have any questions or comments regarding media inquiries, please reach out to mediarelations@mycovia.com.

06.01.2021

Mycovia Pharmaceuticals, Inc. Submits New Drug Application to the U.S. FDA for Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis

Download PDF

01.06.2021

Mycovia Pharmaceuticals, Inc. Announces Positive Topline Results from its Third Phase 3 Clinical Trial (ultraVIOLET) of Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis

Download PDF

12.09.2020

Mycovia Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 VIOLET Studies of Oteseconazole in Patients with Recurrent Vulvovaginal Candidiasis

Download PDF

12.02.2020

Mycovia Pharmaceuticals, Inc. Announces Last Patient Completes Final Visit in their Phase 3 “ultraVIOLET Study” for Oteseconazole (VT-1161) for the Treatment of Recurrent Vulvovaginal Candidiasis (RVVC)

Download PDF

11.02.2020

Mycovia Pharmaceuticals Completes Successful Pre-NDA Meeting with FDA for Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis

Download PDF